Ahmed Abdalhadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Abdalhadi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Mhd Baraa Habib
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
2 shared publications Mohamed A. Yassin
Hamad Medical Corporation, Doha, Qatar
2 shared publicationsNabil E. Omar
Pharmacy Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar
2 shared publications- Abdullatif Al-Khal
Hamad Medical Corporation, Doha, Qatar
1 shared publication - Adnan Humam Waseem Hajjar
Internal Medicine Department, Hamad Medical Corporation, Doha, QAT
1 shared publication Alaaeldin Shablak
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 5 (1) , 22
HPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention
Persistent infection with carcinogenic human papillomavirus (HPV) types causes the great majority of cervical cancers. For more than a decade, randomized trials, surveillance studies, and national registry analyses have demonstrated reductions in vaccine-type HPV infection, high-grade cervical precancer, and invasive cervical cancer following HPV vaccination. Direct evidence regarding cervical cancer mortality has emerged more recently because cohorts vaccinated in early adolescence first had to reach ages at which cervical cancer deaths became observable. A 2026 population-based analysis from England reported no cervical cancer deaths among the most highly vaccinated women aged 20 to 24 years during 2020 to 2024, with substantial mortality reductions also observed in older vaccinated cohorts, although uncertainty increased with age. This narrative review synthesizes the biological and epidemiologic evidence linking HPV vaccination to mortality prevention, critically appraises the England mortality study and its age-stratified findings, considers limitations related to cervical screening and the modeled counterfactual, and discusses implications for cervical cancer elimination, including relevance to Qatar and the wider Eastern Mediterranean region. Current evidence supports early adolescent HPV vaccination as a central cancer-prevention intervention, while continued cervical screening, timely treatment, high and equitable vaccine coverage, and long-term surveillance remain essential. The available mortality evidence is compelling at the population-program level but should not be interpreted as an individual-level randomized estimate of vaccine effectiveness against cervical cancer death.
- 3 October 2026
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 5 (1) , 22
Open AccessHPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention
Persistent infection with carcinogenic human papillomavirus (HPV) types causes the great majority of cervical cancers. For more than a decade, randomized trials, surveillance studies, and national registry analyses have demonstrated reductions in vaccine-type HPV infection, high-grade cervical precancer, and invasive cervical cancer following HPV vaccination. Direct evidence regarding cervical cancer mortality has emerged more recently because cohorts vaccinated in early adolescence first had to reach ages at which cervical cancer deaths became observable. A 2026 population-based analysis from England reported no cervical cancer deaths among the most highly vaccinated women aged 20 to 24 years during 2020 to 2024, with substantial mortality reductions also observed in older vaccinated cohorts, although uncertainty increased with age. This narrative review synthesizes the biological and epidemiologic evidence linking HPV vaccination to mortality prevention, critically appraises the England mortality study and its age-stratified findings, considers limitations related to cervical screening and the modeled counterfactual, and discusses implications for cervical cancer elimination, including relevance to Qatar and the wider Eastern Mediterranean region. Current evidence supports early adolescent HPV vaccination as a central cancer-prevention intervention, while continued cervical screening, timely treatment, high and equitable vaccine coverage, and long-term surveillance remain essential. The available mortality evidence is compelling at the population-program level but should not be interpreted as an individual-level randomized estimate of vaccine effectiveness against cervical cancer death.
- Open Access
- 4 May 2026
- Published by Helixor Scientific Limited in MENA Journal of Case Reports
- Vol. 1 (1) , 30-38
Curative Conversion of Metastatic Gastric Cancer After Pembrolizumab-Trastuzumab-Based Therapy in a PD-L1-Negative, HER2-Positive Patient: A Case Report and Literature Review
Introduction Metastatic gastric cancer (mGC) is a challenging malignancy with poor survival outcomes. Immune checkpoint inhibitors (ICIs), including pembrolizumab, have shown promise in improving responses, particularly in Programmed Death-Ligand 1 (PD-L1)-positive and Microsatellite Instability (MSI)-high tumours. However, based on trial data, only patients with PD-L1-high (Combined Positive Score (CPS) ≥1) or microsatellite-unstable tumours are expected to derive benefit from ICIs. Case Presentation We report a 60-year-old male who presented with epigastric pain, early satiety, and significant weight loss. Esophagogastroduodenoscopy revealed an ulcerated gastric mass, and biopsy confirmed poorly differentiated gastric adenocarcinoma. Staging investigations demonstrated metastatic disease with omental, peritoneal, and distant nodal involvement (cT4N3M1). Immunohistochemistry showed strong HER2 positivity (IHC 3+), PD-L1 negativity (CPS <1), and proficient mismatch repair (pMMR). He was treated with pembrolizumab and trastuzumab-based chemotherapy. Following nine cycles, imaging revealed near-complete radiological response. The patient underwent radical total gastrectomy, splenectomy, omentectomy, and perigastric lymphadenectomy and pathological examination confirmed a complete pathological response (ypT0N0). The patient remains disease free at 28 months post-resection. Discussion This case demonstrates pembrolizumab’s efficacy beyond PD-L1 expression, this is in keeping with previously reported responses in PD-L1-negative patients. The contribution of trastuzumab and cytotoxic agents to the observed response cannot be excluded, as pembrolizumab is not expected to confer benefit in CPS-negative disease per current trial evidence. Conversion surgery, facilitated by systemic therapy, exemplifies a promising approach to improving outcomes in advanced mGC. Conclusion The clinical course observed in this patient suggests that the incorporation of pembrolizumab alongside chemotherapy and targeted therapy may be associated with significant tumour downstaging in select cases of advanced metastatic gastric cancer, even in the setting of PD-L1–negative disease. While causal inference cannot be drawn from a single case, this observation highlights the need for further translational and clinical studies to better understand the biological factors that may underlie such atypical responses.
- 4 May 2026
- Published by Helixor Scientific Limited in MENA Journal of Case Reports
- Vol. 1 (1) , 30-38
Open AccessCurative Conversion of Metastatic Gastric Cancer After Pembrolizumab-Trastuzumab-Based Therapy in a PD-L1-Negative, HER2-Positive Patient: A Case Report and Literature Review
Introduction Metastatic gastric cancer (mGC) is a challenging malignancy with poor survival outcomes. Immune checkpoint inhibitors (ICIs), including pembrolizumab, have shown promise in improving responses, particularly in Programmed Death-Ligand 1 (PD-L1)-positive and Microsatellite Instability (MSI)-high tumours. However, based on trial data, only patients with PD-L1-high (Combined Positive Score (CPS) ≥1) or microsatellite-unstable tumours are expected to derive benefit from ICIs. Case Presentation We report a 60-year-old male who presented with epigastric pain, early satiety, and significant weight loss. Esophagogastroduodenoscopy revealed an ulcerated gastric mass, and biopsy confirmed poorly differentiated gastric adenocarcinoma. Staging investigations demonstrated metastatic disease with omental, peritoneal, and distant nodal involvement (cT4N3M1). Immunohistochemistry showed strong HER2 positivity (IHC 3+), PD-L1 negativity (CPS <1), and proficient mismatch repair (pMMR). He was treated with pembrolizumab and trastuzumab-based chemotherapy. Following nine cycles, imaging revealed near-complete radiological response. The patient underwent radical total gastrectomy, splenectomy, omentectomy, and perigastric lymphadenectomy and pathological examination confirmed a complete pathological response (ypT0N0). The patient remains disease free at 28 months post-resection. Discussion This case demonstrates pembrolizumab’s efficacy beyond PD-L1 expression, this is in keeping with previously reported responses in PD-L1-negative patients. The contribution of trastuzumab and cytotoxic agents to the observed response cannot be excluded, as pembrolizumab is not expected to confer benefit in CPS-negative disease per current trial evidence. Conversion surgery, facilitated by systemic therapy, exemplifies a promising approach to improving outcomes in advanced mGC. Conclusion The clinical course observed in this patient suggests that the incorporation of pembrolizumab alongside chemotherapy and targeted therapy may be associated with significant tumour downstaging in select cases of advanced metastatic gastric cancer, even in the setting of PD-L1–negative disease. While causal inference cannot be drawn from a single case, this observation highlights the need for further translational and clinical studies to better understand the biological factors that may underlie such atypical responses.
- Open Access
- 22 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1275275
Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
Aplastic anemia is a rare hematological disorder characterized by suppressed hematopoiesis and pancytopenia. Although several drugs have been associated with aplastic anemia, its occurrence in response to Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is extremely rare. We present a case report of a 63-year-old patient with locally advanced non-small cell lung cancer (NSCLC) who developed aplastic anemia following adjuvant treatment with Osimertinib. Extensive investigations ruled out infectious etiology, and the absence of bone marrow involvement or other identifiable causes suggested a drug-induced etiology, specifically Osimertinib. This case report emphasizes the importance of recognizing this adverse event and considering it as a potential complication of Osimertinib therapy. Vigilant monitoring and prompt management are essential for optimizing patient outcomes. Further studies are needed to better understand the risk factors, underlying mechanisms, and management strategies for Osimertinib-induced aplastic anemia in the adjuvant settings.
- 22 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1275275
Open AccessAplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
Aplastic anemia is a rare hematological disorder characterized by suppressed hematopoiesis and pancytopenia. Although several drugs have been associated with aplastic anemia, its occurrence in response to Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is extremely rare. We present a case report of a 63-year-old patient with locally advanced non-small cell lung cancer (NSCLC) who developed aplastic anemia following adjuvant treatment with Osimertinib. Extensive investigations ruled out infectious etiology, and the absence of bone marrow involvement or other identifiable causes suggested a drug-induced etiology, specifically Osimertinib. This case report emphasizes the importance of recognizing this adverse event and considering it as a potential complication of Osimertinib therapy. Vigilant monitoring and prompt management are essential for optimizing patient outcomes. Further studies are needed to better understand the risk factors, underlying mechanisms, and management strategies for Osimertinib-induced aplastic anemia in the adjuvant settings.
- Open Access
- 26 December 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 13
The Role of Post-Bronchoscopy Sputum Examination in Screening for Active Tuberculosis
Early diagnosis is a fundamental component of global tuberculosis control. The objective of this study was to evaluate the diagnostic yield of post-bronchoscopy sputum (PBS) testing as part of a tuberculosis diagnostic work-up. All new residents in the State of Qatar undergo a tuberculosis (TB) screening program. Those with abnormal chest radiology, negative sputum acid-fast bacilli (AFB) smears, and nucleic acid amplification testing (NAAT) for M. tuberculosis, undergo an additional bronchoscopic evaluation for TB. We prospectively enrolled individuals who were going to undergo bronchoscopy to provide two PBS samples for AFB smears and mycobacterial cultures between 18 September 2018 and 12 March 2021. A total of 495 individuals, with a median age of 31 years, were included. The majority of the patients were males (329, 66.5%). The most frequent country of origin was India (131, 26.5%) followed by the Philippines (123, 24.8%). The addition of PBS to bronchoalveolar lavage (BAL) testing allowed microbiological confirmation of tuberculosis in an additional 13 patients (3.9%), resulting in improved sensitivity (from 77.9% to 81.9%), negative predictive value (from 69.2% to 73.2%), and negative likelihood ratio (from 0.22 to 0.18). Where resources are available, the incorporation of routine PBS examination as part of tuberculosis diagnostic work-up can enhance the diagnostic yield.
- 26 December 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 13
Open AccessThe Role of Post-Bronchoscopy Sputum Examination in Screening for Active Tuberculosis
Early diagnosis is a fundamental component of global tuberculosis control. The objective of this study was to evaluate the diagnostic yield of post-bronchoscopy sputum (PBS) testing as part of a tuberculosis diagnostic work-up. All new residents in the State of Qatar undergo a tuberculosis (TB) screening program. Those with abnormal chest radiology, negative sputum acid-fast bacilli (AFB) smears, and nucleic acid amplification testing (NAAT) for M. tuberculosis, undergo an additional bronchoscopic evaluation for TB. We prospectively enrolled individuals who were going to undergo bronchoscopy to provide two PBS samples for AFB smears and mycobacterial cultures between 18 September 2018 and 12 March 2021. A total of 495 individuals, with a median age of 31 years, were included. The majority of the patients were males (329, 66.5%). The most frequent country of origin was India (131, 26.5%) followed by the Philippines (123, 24.8%). The addition of PBS to bronchoalveolar lavage (BAL) testing allowed microbiological confirmation of tuberculosis in an additional 13 patients (3.9%), resulting in improved sensitivity (from 77.9% to 81.9%), negative predictive value (from 69.2% to 73.2%), and negative likelihood ratio (from 0.22 to 0.18). Where resources are available, the incorporation of routine PBS examination as part of tuberculosis diagnostic work-up can enhance the diagnostic yield.
- Open Access
- 15 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20439
Pleural Effusion Revealing a Diagnosis of Ewing Sarcoma
Pleural effusion can rarely present as an initial manifestation of Ewing sarcoma. We illustrate a case of a young male adult who was admitted with pleural effusion that led to the diagnosis of Ewing sarcoma.
- 15 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20439
Open AccessPleural Effusion Revealing a Diagnosis of Ewing Sarcoma
Pleural effusion can rarely present as an initial manifestation of Ewing sarcoma. We illustrate a case of a young male adult who was admitted with pleural effusion that led to the diagnosis of Ewing sarcoma.
- Open Access
- 26 May 2020
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2) , 578-582
Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Here, we report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.
- 26 May 2020
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2) , 578-582
Open AccessParathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Here, we report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.
- Open Access
- 19 May 2020
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2) , 569-577
Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome
Coronavirus disease-19 is a respiratory viral disease that commonly presents with mild symptoms. However, it can cause serious complications such as acute respiratory disease, especially in patients with comorbidities. As it is a new disease, the full picture of the disease and its complications are not yet fully understood. Moreover, the patients at risk of complications are not well identified; and the data about the risk in patients with hematological malignancies is limited. Here, we report a 65-year-old male with accelerated phase chronic myeloid leukemia, on dasatinib, tested positive for coronavirus disease-19, then complicated with febrile neutropenia acute respiratory distress syndrome.
- 19 May 2020
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2) , 569-577
Open AccessConfirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome
Coronavirus disease-19 is a respiratory viral disease that commonly presents with mild symptoms. However, it can cause serious complications such as acute respiratory disease, especially in patients with comorbidities. As it is a new disease, the full picture of the disease and its complications are not yet fully understood. Moreover, the patients at risk of complications are not well identified; and the data about the risk in patients with hematological malignancies is limited. Here, we report a 65-year-old male with accelerated phase chronic myeloid leukemia, on dasatinib, tested positive for coronavirus disease-19, then complicated with febrile neutropenia acute respiratory distress syndrome.